Zebrafish model could help unlock Parkinson’s disease mechanisms

Nearly one million people in the United States are living with Parkinson’s disease, making it the second-most common neurodegenerative disease after Alzheimer’s.

Sanofi shakes up clinical plans for trio of programs from Denali, Principia and Kymab deals

Sanofi is shuffling its pipeline after several trial flops in anti-inflammatory and cancer drugs it landed through a partnership with Denali and buyouts of Principia

October 28, 2023

Risk adjusted net present value: What is the current valuation of Kissei Pharmaceutical’s Cretostimogene Grenadenorepvec?

Cretostimogene Grenadenorepvec is an oncolytic virus commercialized by Kissei Pharmaceutical, with a leading Phase III program in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder

March 14, 2024

Study shows significant drop in insulin costs after colorado caps prices

Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year. This chronic condition is one of the leading causes of death in

September 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.